%0 Journal Article
%A Torrente-Segarra, Vicenc
%A Urruticoechea Arana, Ana
%A Sanchez-Andrade Fernandez, Amalia
%A Tovar Beltran, Juan Victor
%A Munoz Jimenez, Alejandro
%A Martinez-Cristobal, Anna
%A Gonzalez Ferrandez, Jose Antonio
%A Fernandez Prada, Manuel
%A Vazquez Fuentes, Noelia
%A Corominas, Hector
%A Garcia-Diaz, Silvia
%A Acosta Pereira, Asuncion
%A Ruiz Martin, Jose Miguel
%A Lamua Riazuelo, Jose Ramon
%A Exposito Moliner, Rosa
%A Ruiz Vilchez, Desiree
%A Veiga Cabello, Raul
%A Carlos Fernandez, Jesus
%A Noguera Pons, Jose Raul
%A Garrido Punal, Noemi Patricia
%A Giralt Celimendiz, Pedro
%A Cortes Verdu, Raul
%A Aragon Diez, Angel
%A Tomas Roura, Carlos
%A Moll Turudi, Concepcion
%A Taverner Torrent, Delia
%A Rivas Santirso, Felipe Joaquin
%A Lerma Garrido, Juan Jose
%A Garcia Portales, Rosa
%A Ordonez Palau, Sergi
%A Paredes Gonzalez-Albo, Silvia
%A Gracia Perez, Antonio
%A Conesa Mateos, Arantxa
%A Calvo Alen, Jaime
%A Grana Gil, Jenaro
%A Navarro Alonso, Maria Pilar
%A Martinez Blasco, Maria Jesus
%A RENACER StudyGrp
%T RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database
%D 2016
%@ 1439-7595
%U http://hdl.handle.net/10668/19206
%X Objective: To assess effectiveness and safety of certolizumab PEGol (CZP) in rheumatoid arthritis (RA) patients after 12 months of treatment and to detect predictors of response.Methods: Observational longitudinal prospective study of RA patients from 35 sites in Spain. Variables (baseline, 3- and 12-month assessment): sociodemographics, previous Disease Modifying Anti-Rheumatic Drug (DMARD) and previous Biological Therapies (BT) use; TJC, SJC, ESR, CRP, DAS28, SDAI. Response variables: TJC, SJC, CRP, ESR, and steroids dose reductions, EULAR Moderate/Good Response, SDAI response and remission, DAS28 remission. Safety variables: discontinuation due to side-effects. Descriptive, comparative and Logistic regression analyses were performed.Results: We included 168 patients: 79.2% women, mean age 54.5 years (+/- 13.2 SD), mean disease duration 7.5 years (+/- 7.3 SD). Mean number of prior DMARD: 1.4 (+/- 1.2 SD), mean number of prior BT was 0.8 (+/- 1.1). Mean time on CZP was 9.8 months (+/- 3.4 SD). A total of 71.4% were receiving CZP at 12-month assessment. Baseline predictors of response: lower prior number DMARD; low number prior BT; higher CRP, ESR, TJC, SJC, DAS28 and SDAI (p
%K Certolizumab PEGol
%K Clinical practice
%K Efficacy
%K Rheumatoid arthritis
%K Safety
%K Spanish population
%K Survival rate
%K College-of-rheumatology
%K Danish danbio registry
%K Anti-tnf therapy
%K Clinical-practice
%K Long-term
%K Plus methotrexate
%K Japanese patients
%K Gisea registry
%K Alpha agents
%K Adalimumab
%~